The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review

Cardiology and Therapy

Volumn 2, Issue 1, 2013, Pages 17-25

  Banerjee, Subhash ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiology; Coronary artery disease; Diabetes mellitus; Drug eluting stent; Percutaneous cardiovascular intervention; Zotarolimus eluting stent

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HUMAN; INCIDENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; REVIEW; SCORING SYSTEM; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 84992002358     PISSN: 21938261     EISSN: 21936544     Source Type: Journal    
DOI: 10.1007/s40119-012-0010-z     Document Type: Review

References (37)

1. Katritsis DG, Karvouni E, Ioannidis JP. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol. 2005;95: 640-3.
2. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370: 937-48.
3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Eng J Med. 2007;356: 1030-9.
4. Lee SW, Chan MP, Chan KK. Acute and 16-month outcomes of a new stent: the first-in-man evaluation of the Medtronic S9 (integrity) stent. Catheter Cardiovasc Interv. 2011;78: 898-908.
5. Ormiston JA, Webber B, Webster MW. Stent longitudinal integrity bench insights into a clinical problem. JACC Cardiovasc Interv. 2011;4: 1310-7.
6. Ormiston JA, Dixon SR, Webster MW, et al. Stent longitudinal flexibility: a comparison of 13 stent designs before and after balloon expansion. Catheter Cardiovasc Interv. 2000;50: 120-4.
7. Escaned J, Goicolea J, Alfonso F, et al. Propensity and mechanisms of restenosis in different coronary stent designs: complementary value of the analysis of the luminal gain-loss relationship. J Am Coll Cardiol. 1999;34: 1490-7.
8. Kastrati A, Dirschinger J, Boekstegers P, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1, 147 unselected patients. Catheter Cardiovasc Interv. 2000;50: 290-7.
9. Kastrati A, Mehilli J, Dirschinger J, et al. Restenosis after coronary placement of various stent types. Am J Cardiol. 2001;87: 34-9.
10. Mortier P, De Beule M, Segers P, Verdonck P, Verhegghe B. Virtual bench testing of new generation coronary stents. EuroIntervention. 2011;7: 369-76.
11. Udipi K, Melder RJ, Chen M, et al. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention. 2007;3: 137-9.
12. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009;2: 977-85.
13. Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3: 50-3.
14. Mauri L, Leon MB, Yeung AC, Negoita M, Keyes MJ, Massaro JM. Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). Am Heart J. 2011;161: 807-14.
15. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57: 1778-83.
16. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363: 136-46.
17. Stefanini GG, Serruys PW, Silber S, et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol. 2011;57: 2221-32.
18. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377: 1241-7.
19. Silber S, Windecker S, Serruys PW, on behalf of the RESOLUTE All Comers Investigators. Three-year outcomes from the randomized comparison of a Zotarolimus-eluting stent and an everolimus-eluting stent in the RESOLUTE All Comers Trial. EuroIntervention. 2012;8(Suppl. N): N16.
20. Neumann FJ, Widimsky P, Belardi JA. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. EuroIntervention. 2012;7: 1181-8.
21. Yeung AC, Leon M, Silber S, et al. The Resolute zotarolimus-eluting stent in patients with diabetes mellitus: two year outcomes. J Am Coll Cardiol. 2012;59(13 Suppl.): E97.
22. Mauri L, Leon M, Yeung A, et al. The Resolute zotarolimus-eluting stent in patients with diabetes mellitus: one year outcomes. Eurointervention. 2011;7(Suppl. M).
23. Stefanini GG, Kalesan B, Pilgrim T, et al. Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. JACC Cardiovasc Interv. 2012;5: 301-10.
24. Garg S, Sarno G, Serruys PW, et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention. 2010;6: 233-9.
25. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375: 201-9.
26. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117, 762 patient-years of follow-up from randomized trials. Circulation. 2012;125: 2873-91.
27. von Birgelen C, Basalus MWZ, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59: 1350-61.
28. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30: 2441-9.
29. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011;124: 624-32.
30. Romagnoli E, Godino C, Ielasi A, et al. Resolute Italian study in all comers: immediate and one-year outcomes. Catheter Cardiovasc Interv. 2012;79: 567-74.
31. Krucoff MW, Rutledge DR, Gruberg L, et al. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc Interv. 2011;4: 1298-309.
32. Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents/clinical perspective. Circulation. 2011;123: 2819-28.
33. Raber L, Juni P, Nuesch E, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol. 2011;57: 2143-51.
34. de la Torre Hernandez JM, Alfonso F, Gimeno F, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv. 2010;3: 911-9.
35. Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2008;102: 1328-34.
36. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124: 893-900.
37. Jensen LO, Thayssen P, Junker A, et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV Trial). Am J Cardiol. 2012;110: 1585-91.